Sigyn Therapeutics Inc - SIGY STOCK NEWS

Welcome to our dedicated news page for Sigyn Therapeutics (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sigyn Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sigyn Therapeutics's position in the market.

03/05/2024 09:00 AM

News

Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference

Rhea-AI Summary

Sigyn Therapeutics, Inc. announces CEO Jim Joyce's live presentation at the Emerging Growth Conference to update on Sigyn TherapyTM and new cancer treatment products. The presentation will focus on a novel blood purification technology for life-threatening conditions and products to enhance chemotherapy and immunotherapy benefits.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.26%

Tags

02/21/2024 08:45 AM

News

Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K

Rhea-AI Summary

Sigyn Therapeutics, Inc. filed its Form 10-K annual report with the SEC for 2023, introduced new therapeutic candidates, and prepared for first-in-human clinical studies. The company reported a loss from operations of $2.5 million and a net loss of $4.1 million for 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/01/2024 06:25 PM

News

Sigyn Therapeutics Completes Reverse Stock Split

Rhea-AI Summary

Sigyn Therapeutics, Inc. announced a 1-for-40 reverse stock split, with the common stock trading under the ticker symbol 'SIGYD' for 20 days and then reverting to 'SIGY' on February 29, 2024. The Company also reported 1,221,043 common shares issued and outstanding as of January 31, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/30/2024 08:45 AM

News

Sigyn Therapeutics Announces Reverse Stock Split

Rhea-AI Summary

Sigyn Therapeutics, Inc. announced a 1-for-40 reverse split of its common stock to increase the market price per share and gain compliance with the minimum bid listing requirement of The Nasdaq Capital Market. The reverse split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4551.16%

Tags

01/04/2024 08:00 AM

News

Sigyn Therapeutics Releases Letter to Shareholders

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) announces release of shareholder letter by Chairman and CEO, Jim Joyce, detailing the company's development-stage medical technology and prospects for its therapies. The letter provides an update on proposed underwritten financing and discusses the development of Sigyn TherapyTM, ImmunePrepTM, ChemoPrepTM, and ChemoPureTM platforms.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/12/2023 08:30 AM

News

Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) appoints Jerry DeCiccio, CPA, MBA, as Chief Financial Officer, bringing over 40 years of financial industry experience to the Company. Mr. DeCiccio has held executive roles at publicly traded companies, including Intech Electromechanical, GTC Telecom, Incomnet Communications, and Cerebain Biotech Corp. He has also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc., and Newport Corp. Mr. DeCiccio's appointment follows the tenure of Jeremy Farrell, who was previously appointed CFO in March of 2022. The company expresses its appreciation for Farrell's service and looks forward to focusing on the clinical advancement of Sigyn Therapy and unlocking the value of its therapeutic pipeline with Jerry DeCiccio on board.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-28.21%

Tags

11/14/2023 05:11 PM

News

Sigyn Therapeutics Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTCQB: SIGY) announces financial results for Q3 2023, highlighting plans for first-in-human studies of Sigyn TherapyTM and pipeline technologies to enhance cancer therapies. The Company aims to address end-stage renal disease (ESRD) patients with endotoxemia, with a focus on safety. Financially, Sigyn had a loss from operations of approximately $642,814, and a net loss of approximately $905,726 for the quarter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/04/2023 08:30 AM

News

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Rhea-AI Summary

Sigyn Therapeutics submits a Patent Cooperation Treaty (PCT) application to enhance chemotherapy delivery and reduce toxicity. The company is developing ChemoPrepTM and ChemoPureTM technologies to increase tumor-site saturation of chemotherapy agents with reduced doses. This may improve treatment outcomes, alleviate supply chain issues, and enhance patient quality of life. No concrete business takes affecting stock price are mentioned.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/06/2023 08:00 AM

News

Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference

Rhea-AI Summary

Sigyn Therapeutics, Inc. announces online presentation at Emerging Growth Conference and in-person presentation at NIBA Conference.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/14/2023 04:30 PM

News

Sigyn Therapeutics Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) announces financial results for Q2 2023, including a focus on first-in-human studies of Sigyn TherapyTM and the introduction of ImmunePrepTM, a platform designed to enhance the delivery of immunotherapeutic antibodies. The company reported a loss from operations of approximately $574,009 and a net loss of approximately $723,124 for the quarter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12%

Tags